20:40:59 EDT Fri 19 Apr 2024
Enter Symbol
or Name

Login ID:
Revive Therapeutics Ltd
Symbol RVV
Shares Issued 308,417,884
Close 2021-09-21 C$ 0.46
Market Cap C$ 141,872,227
Recent Sedar Documents

Revive joins AdvisorShares Psychedelics ETF

2021-09-21 12:50 ET - News Release

Mr. Michael Frank reports


AdvisorShares Investments LLC, a leading sponsor of actively managed exchange-traded funds (ETF), has included Revive Therapeutics Ltd. in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).

PSIL invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical and life sciences companies leading the way in this nascent industry. The ETF at launch includes 16 publicly listed companies offering investors exposure to companies that are leading the way in the emerging psychedelics space.

"We are pleased to be included in the inaugural launch of the PSIL ETF as it provides further validation of our pharmaceutical psychedelics strategy in pursuing novel uses, formulations and delivery forms of psilocybin for the treatment of mental health and neurological conditions," said Michael Frank, chief executive officer of the company.

PSIL commenced trading on Sept. 16, 2021, debuting on the New York Stock Exchange under ticker symbol PSIL. The holdings of PSIL and its current portfolio weights are regularly updated and available on-line.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA (Food and Drug Administration) such as orphan drug, fast-track, breakthrough therapy and rare pediatric disease designations. Currently, the company is exploring the use of bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.